Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

Inclusion Criteria:

* Hormone-refractory prostate cancer patients
* Three consecutive rises of PSA min. 2 weeks apart, resulting in at least two 50% increases over the PSA nadir.
* Antiandrogen withdrawal for at least 4 weeks, or
* PSA progression despite secondary hormonal manipulations, or
* Progression of osseous or soft tissue lesions.
* Serum castration levels of testosterone.
* Be capable of understanding the information and giving informed consent.
* Expected survival time (life expectancy) of over 4 months.
* Adequate performance status (WHO / ECOG Performance status score 2 or less).

Exclusion Criteria:

* Patients with a low blood count (haemoglobin \< 6.0 mmol/l).
* Patients with lymphocyte-numbers below 0.8.
* Patients known to be HIV and/or hepatitis positive i.e. patients positive in tests for anti-HIV-1/2; HBsAg, anti-HBc and Anti-HCV.
* Patients known to have syphilis i.e. being positive in a Treponema Pallidum test.
* Patients with uncontrolled serious bacterial, viral, fungal or parasitic infection.
* Patients must have no clinically significant autoimmune disorders or conditions of immune suppression.
* Patients that have been treated with corticosteroids (steroid hormones) or bisphosphonates or have been in chemotherapy or radiation treatment one month prior to inclusion in the clinical trial.
* Fertile patients.
* Patients that have received blood transfusions within 48 hours prior to donation of blood for ALECSAT production.
* Patients must not have been included in other clinical trials 6 weeks prior to inclusion in the trial or be enrolled in other clinical trials during the ALECSAT clinical trial.
* Any medical condition that will render participation in the study risky or, according to the investigator in charge, will make the assessment of side-effects difficult.